Andrea N Edginton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6708971/publications.pdf

Version: 2024-02-01

58 papers	1,969 citations	279701 23 h-index	254106 43 g-index
59 all docs	59 docs citations	59 times ranked	1939 citing authors

#	Article	IF	Citations
1	Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children. Clinical Pharmacokinetics, 2006, 45, 1013-1034.	1.6	288
2	Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs. Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34, 401-431.	0.8	199
3	A Mechanistic Approach for the Scaling of Clearance in Children. Clinical Pharmacokinetics, 2006, 45, 683-704.	1.6	186
4	Physiology-Based Simulations of a Pathological Condition. Clinical Pharmacokinetics, 2008, 47, 743-752.	1.6	144
5	Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death. Cancer Research, 2015, 75, 2478-2488.	0.4	136
6	Development of a Web-Accessible Population Pharmacokinetic Serviceâ€"Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Research Protocols, 2016, 5, e239.	0.5	86
7	A Blended Learning Approach to Teaching Basic Pharmacokinetics and the Significance of Face-to-Face Interaction. American Journal of Pharmaceutical Education, 2010, 74, 88.	0.7	63
8	Open Systems Pharmacology Communityâ€"An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 878-882.	1.3	58
9	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	1.0	50
10	Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility. Pharmaceutical Research, 2016, 33, 52-71.	1.7	48
11	Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 585-599.	1.5	48
12	The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1313-1321.	1.5	44
13	Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). JMIR Research Protocols, 2016, 5, e232.	0.5	43
14	Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation. Pharmaceutics, 2019, 11, 179.	2.0	35
15	Comparative pharmacokinetics of two extended halfâ€life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. Journal of Thrombosis and Haemostasis, 2019, 17, 1085-1096.	1.9	34
16	Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Pharmaceutical Research, 2017, 34, 2579-2595.	1.7	30
17	Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on <scp>ECMO</scp>. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 629-637.	1.3	29
18	Quantifying breast milk intake by term and preterm infants for input into paediatric physiologically based pharmacokinetic models. Maternal and Child Nutrition, 2020, 16, e12938.	1.4	27

#	Article	IF	Citations
19	Physiologicallyâ€Based Pharmacokinetic Modeling Characterizes the CYP3Aâ€Mediated Drugâ€Drug Interaction Between Fluconazole and Sildenafil in Infants. Clinical Pharmacology and Therapeutics, 2021, 109, 253-262.	2.3	27
20	Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPSâ€Hemo project. Haemophilia, 2020, 26, 384-400.	1.0	26
21	Predicting Escitalopram Exposure to Breastfeeding Infants: Integrating Analytical and In Silico Techniques. Clinical Pharmacokinetics, 2018, 57, 1603-1611.	1.6	25
22	Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 411-426.	0.8	25
23	Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 277-290.	0.8	24
24	Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study. Thrombosis and Haemostasis, 2019, 119, 368-376.	1.8	22
25	Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants. Journal of Clinical Pharmacology, 2020, 60, 466-476.	1.0	21
26	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	1.0	18
27	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (AdynovateÂ®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clinical Pharmacokinetics, 2020, 59, 245-256.	1.6	18
28	A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease. Journal of Clinical Pharmacology, 2020, 60, S52-S62.	1.0	18
29	Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. Pharmaceutics, 2017, 9, 47.	2.0	17
30	Model qualification of the PK-SimÂ® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2019, 82, 789-814.	1.1	15
31	Physiologicallyâ€Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 500-510.	1.3	13
32	Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics, 2022, 61, 307-320.	1.6	13
33	Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology. Journal of Clinical Pharmacology, 2018, 58, S73-S85.	1.0	12
34	Terminal halfâ€life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. Journal of Thrombosis and Haemostasis, 2021, 19, 1896-1906.	1.9	12
35	Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 814-822.	1.3	10
36	Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study. Haemophilia, 2021, 27, 358-365.	1.0	9

#	Article	IF	Citations
37	Assessment of Vehicle Volatility and Deposition Layer Thickness in Skin Penetration Models. Pharmaceutics, 2021, 13, 807.	2.0	9
38	Pediatric Dose Selection for Therapeutic Proteins. Journal of Clinical Pharmacology, 2021, 61, S193-S206.	1.0	9
39	Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 427-438.	0.8	8
40	What is the role for population pharmacokinetics in hemophilia?. International Journal of Pharmacokinetics, 2017, 2, 125-136.	0.5	7
41	Clinical application of Web Accessible Population Pharmacokinetic Serviceâ€"Hemophilia (WAPPSâ€Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia, 2020, 26, 56-63.	1.0	7
42	Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature. Clinical Pharmacokinetics, 2022, 61, 189-229.	1.6	7
43	Parameterization of small intestinal water volume using PBPK modeling. European Journal of Pharmaceutical Sciences, 2015, 67, 55-64.	1.9	6
44	Incorporating Breastfeeding-Related Variability with Physiologically Based Pharmacokinetic Modeling to Predict Infant Exposure to Maternal Medication Through Breast Milk: a Workflow Applied to Lamotrigine. AAPS Journal, 2021, 23, 70.	2.2	5
45	Use of <scp>physiologicallyâ€based</scp> pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 778-791.	1.3	5
46	Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population. Drug Metabolism and Disposition, 2021, 49, 844-855.	1.7	4
47	Development and Evaluation of an In Silico Dermal Absorption Model Relevant for Children. Pharmaceutics, 2022, 14, 172.	2.0	4
48	A Mechanistic Bayesian Inferential Workflow for Estimation of In Vivo Skin Permeation from In Vitro Measurements. Journal of Pharmaceutical Sciences, 2022, 111, 838-851.	1.6	4
49	Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence. Frontiers in Pediatrics, 2022, 10, .	0.9	4
50	Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. Veterinary Anaesthesia and Analgesia, 2016, 43, 35-43.	0.3	3
51	A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients. Thrombosis Research, 2019, 184, 31-37.	0.8	3
52	A personalized limited sampling approach to better estimate terminal halfâ€life of <scp>FVIII</scp> concentrates. Journal of Thrombosis and Haemostasis, 0, , .	1.9	3
53	A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. Thrombosis Research, 2020, 196, 550-558.	0.8	2
54	Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies. Pharmaceutical Research, 2022, 39, 239.	1.7	2

#	Article	IF	Citations
55	Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics, 2022, 61, 997-1012.	1.6	2
56	Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. HemaSphere, 2022, 6, e694.	1.2	1
57	External qualification of the Webâ€Accessible Population Pharmacokinetic Serviceâ€“Hemophilia (WAPPSâ€Hemo) models for octocog alfa using real patient data. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12599.	1.0	0
58	Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis. Pharmaceutics, 2022, 14, 356.	2.0	0